Modern possibilities of treatment of chronic inflammatory diseases of the genital organs in women of fertile age

Authors: Vl.V. Podolsky, V.V. Podolsky, SE «Institute of Pediatrics, Obstetrics and Gynecology of the National Academy of Medical Sciences of Ukraine», Kyiv


The objective

To evaluate the outpatient treatment of chronic pelvic inflammatory diseases of fertile aged women caused by mixed infection, including Chlamydia.

Patients and methods

We examined 100 women chronic pelvic inflammatory diseases determining vaginal microbiota condition before and after treatment. Provided research of efficiency in the treatment of drug containing ciprofloxacin – and ornidazole 500 mg – 500 mg (Ortsypol) in women with chronic pelvic inflammatory diseases in lower levels of genital tract.

Analysis of the vaginal bacterial spectrum and records of the results was performed according to the order number 234 of the Ministry of Health of Ukraine 2005

Results

Our results have shown that most women suffered from chronic pelvic inflammatory diseases in lower level of genital tract during one year (30%), slightly less women had disease duration of 3 years (27%) and 5 years (25%).

Among other gynecological diseases in examined women often diagnosed cervical erosion (14%) and the polycystic ovarian syndrome (18%). Often diagnosed ovarian cysts (10%), endometriosis (11%) and endometrial hyperplasia (9%).

Examination of vaginal mikrobiome in fertile aged women with chronic pelvic inflammatory diseases showed increased number of resident microflora and STIs, mainly: Chlamidya trahomatis (25%), Ureaplasma urealiticum (23%).

We observed significant reduction of the number of pathogenic and conditionally pathogenic microflora in fertile aged women with chronic pelvic inflammatory diseases after treatment rizke.

Conclusion

  1. The most common cause of vaginal dysbiosis in women that were attending outpatient clinic, were sexually transmitted infections, among which most commonly we diagnosed Chlamidya trahomatis.
  2. In the development of inflammatory reactions in reproductive organs and chronic pelvic inflammatory diseases main role-plays microbial and viral and microbial associations in which Chlamidya trahomatis and Ureaplasma urealiticum are present.
  3. Use of a complex chronic pelvic inflammatory diseases treatment of lower genital tract using Ortsypol shown to be highly effective (95%).

Key words: chronic inflammatory diseases, fertile aged women, infections, sexually transmitted infections, outpatient treatment, Ortsypol.

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design